RxDoctor Payments Data

Jon Derksen, MD

Urology · Colorado Springs, CONPI 1649254905

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $7,122 of the $8,787 with a category attached, or 81.1%. 44 manufacturers reported payments, led by Angiodynamics, Inc. at 24.9% of the total. Reporting peaked in 2023 at $3,130 and has fallen 75.5% since, to $765 in 2025.

$8,787in general payments, 2019–2025

Across 347 payments — averaging $25.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$2K
  • Astellas Pharma US Inc$1K
  • AbbVie$714
  • Pfizer$605
  • Johnson & Johnson$389
  • Endo Pharmaceuticals Inc.$381
  • plus $3K from 38 others

What the payments were for

  • Travel & lodging$1,05012%
  • Food & beverage$7,12281%
  • Education$6157%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,787 in reported general payments places this provider in the 75th percentile of 225 urology providers in Colorado.

See all urology providers in Colorado

Medicare billing

Part B allowed, 2024
$425,467
Medicare patients
483
Services billed
10,029

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NubeqaDarolutamide62$810,281
ErleadaApalutamide35$504,791
Abiraterone Acetate308$426,084
OrgovyxRelugolix116$301,145
YonsaAbiraterone Acet,submicronized24$268,890
XtandiEnzalutamide14$194,538
MyrbetriqMirabegron63$71,463
Tamsulosin Hcl281$5,884
Dutasteride109$4,935
Finasteride273$3,856
Megestrol Acetate24$2,921
Prednisone273$1,528
Solifenacin Succinate16$1,112
Testosterone Cypionate21$1,074
Celecoxib23$785

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerNubeqa$236$810,28162 claims
Johnson & JohnsonErleada$389$504,79135 claims
Sumitomo Pharma America, Inc.Orgovyx$67$301,145116 claims
Astellas Pharma US IncXtandi, Myrbetriq$1,300$266,00177 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 225 urology providers in Colorado.

Other urology in Colorado Springs

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →